Abpro Holdings, Inc.
Public company- Headquarters
- NEW YORK, New York
- Industry
- Biotechnology
- Ticker
- ABPO
- CIK
- 0001893219
WARN notices since 2024
Workers affected since 2024
Executive changes, last 12 months
Last event
Workers affected over time
Cumulative workers in WARN notices since 2024
Not enough notices to chart yet.
Leadership
| Role and person | Since | Change |
|---|---|---|
| Chairman of the Board of DirectorsMiles Suk | Sep 1, 2026 | Departed |
| CEOMiles Suk | Aug 25, 2026 | Departed |
| CEOM. Fatih Karatas | Aug 25, 2026 | Appointed |
Related companies
Same industry and state, with recent events.
- ANAVEX LIFE SCIENCES CORP.
CEO appointed: Terrie Kellmeyer, Ph.D.
- MeiraGTx Holdings plc
Class I director appointed: Alan M. Sebulsky
- RECURSION PHARMACEUTICALS, INC.
Chair of the Board appointed: Fred Hassan
- Vir Biotechnology, Inc.
Class III director appointed: Suzanne Topalian, M.D.
- Executive departure
Chairman of the Board of Directors departs: Miles Suk
Miles Suk, Chairman of the Board of Directors of Abpro Holdings, Inc., resigns the role, effective August 25, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Sep 1, 2026Role: Chairman of the Board of Directors
- Executive departure
CEO departs: Miles Suk
Miles Suk, Chief Executive Officer of Abpro Holdings, Inc., resigns the role, effective August 19, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Aug 25, 2026Role: Chief Executive Officer
- Executive appointment
CEO appointed: M. Fatih Karatas
M. Fatih Karatas was named Interim Chief Executive Officer of Abpro Holdings, Inc., effective August 25, 2026. M. Fatih Karatas succeeds Miles Suk. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Aug 25, 2026Role: Interim Chief Executive Officer
Last verified Nov 8, 2026